Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO(R)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO(R) (latanoprostene bunod)

Meets Primary Endpoint in Phase 3 Studies

Expect to file in the U.S. in First Half of Q2 2015

Expect to launch in the U.S. in First Half of 2016

Peak US sales ~$500 million+, Peak Global Sales ~$1 billion+

LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) today announced positive top-line results from the pivotal Phase 3 studies conducted with VESNEO (latanoprostene bunod; previously known as BOL-303259-X and NCX 116) for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.  VESNEO is a novel nitric oxide-donating prostaglandin F2-alpha analog licensed by Nicox to Bausch + Lomb. These studies met their primary endpoint and showed positive results on a number of secondary endpoints. This product has peak sales potential of ~$500 million+ in the U.S. alone and ~$1 billion+ globally. These positive results follow three successful approvals from the Food and Drug Administration (FDA) in the last year, including approvals for  Luzu ® (luliconazole) Cream Jublia ® (efinaconazole 10% topical solution) and Retin-A Micro (tretinoin) Gel microsphere 0.08%, and further validate our unique output-driven approach to R&D.

"The results of these studies confirm the results observed in the phase 2b trials. VESNEO  effectively lowered IOP, which is critical in the management of glaucoma or ocular hypertension, and was well-tolerated" said Robert N. Weinreb, M.D., chairman & distinguished professor of Ophthalmology and director, Hamilton Glaucoma Center at the University of California San Diego. 

"Valeant is committed to innovation in healthcare and continues to fund important R&D programs that will bring benefits to physicians and the patients they serve," stated J. Michael Pearson, chairman and chief executive officer, Valeant Pharmaceuticals International, Inc. "We are pleased with the Phase 3 program top line results and look forward to continuing to advance the VESNEO program as part of this commitment. We are proud of our R&D Team who have worked diligently over the past four years to bring this program to successful completion. We are pursuing development plans and programs for other priority markets around the world."

"VESNEO was discovered in our Research Laboratories in Milan and we are encouraged by these promising results from Bausch + Lomb's pivotal Phase 3 studies," said Michele Garufi, chairman and CEO of Nicox. "The success of this program thus far highlights the promise of nitric oxide donation in the treatment of serious ophthalmic conditions and we are delighted by Valeant's commitment to bringing a new treatment option to patients."

Phase 3 study design and top-line results

The pivotal Phase 3 program includes two separate randomized, multicenter, double-masked, parallel-group clinical studies, APOLLO and LUNAR, designed to compare the efficacy and safety of VESNEO administered once daily (QD) against timolol maleate 0.5% administered twice daily (BID) in lowering IOP in patients with open-angle glaucoma or ocular hypertension. The primary endpoint of both studies, which include a combined total of 840 patients, was the reduction in mean IOP measured at specified time points during three months of treatment. The collection of patient safety data for a total of up to 12 months is still ongoing. The Phase 3 studies are pivotal for U.S. registration and are being conducted in North America and Europe. Additional information about the studies can be found at www.clinicaltrials.gov .

The primary endpoint of non-inferiority to timolol maleate 0.5% was achieved in both Phase 3 studies.  Additionally, VESNEO showed a reduction in mean IOP of 7.5 to 9.1 mmHg from baseline between 2 and 12 weeks of treatment in the two Phase 3 studies. This IOP effect was statistically superior (p < 0.05) to timolol in both studies. VESNEO also showed positive results on a number of secondary endpoints. There were no significant safety findings in either study.

Bausch + Lomb expects to submit a new drug application to the FDA for the approval of VESNEO in mid-2015.

About Glaucoma

Glaucoma is a group of eye diseases which can lead to the loss of peripheral vision and eventually total blindness. Glaucoma is frequently linked to abnormally high pressure in the eye (intraocular pressure, IOP), due to blockage or malfunction of the eye's drainage system. Abnormally high IOP does not cause any symptoms itself, however it can lead to optic nerve damage and vision loss if left untreated. Drug therapy is used to reduce IOP and therefore prevent further vision loss, typically through increasing the drainage of intraocular fluid by relaxing certain muscles in the eye. Several large trials have demonstrated that reducing IOP can prevent the progression of glaucoma in both early and late stages of the disease. A significant proportion of patients with elevated IOP require more than one medication to maintain their IOP within target levels, highlighting the need for more effective treatments.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com .

About Bausch + Lomb

Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries.

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod) (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com .

Valeant Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding expected regulatory filings, commercialization plans, product potential, future investment in R&D programs and the related benefits and effects of such programs. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Nicox Forward -looking Statement

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2013 » filed with the French Autorité des Marchés Financiers (AMF) on April 2nd, 2014 and available on Nicox' website ( www.nicox.com ) and on the AMF's website ( www.amf-france.org ).

©Bausch & Lomb Incorporated

Contacts:

Valeant Pharmaceuticals International, Inc.
Investors:
Laurie Little
SVP, Investor Relations
(949) 461-6002 or laurie.little@valeant.com

Financial Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com

Kristy Marks
Public Relations Product Manager, Bausch + Lomb
(585) 338-8095 or kristy.marks@bausch.com

Nicox S.A.
Gavin Spencer 
Executive Vice President Corporate Development, Nicox
+33 (0)4 97 24 53 00 or communications@nicox.com
Jonathan Birt, on behalf of Nicox
+44 7860 361 746  |  jonathan.birt@ymail.com

Press release http://hugin.info/143509/R/1858182/650764.pdf

HUG#1858182

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 128

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 117

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 102

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 33

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 61

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 134

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 122

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading

Top 5 Most Recently Viewed Articles

Axiom Foods Unveils Neutral Pea Protein Amid Market Challenges

Updated Category News Views 292

Revolutionizing the U.S. Pea Protein Market The U.S. pea protein sector is undergoing significant transformations driven by recent tariff regulations. As steep tariffs were imposed on Chinese imports, the challenges in supply chains have heightened. Axiom Foods is stepping up its game to become a key player in the industry by introducing its innovative product,...

Continue Reading
Cabaletta Bio's Transformative Developments in Autoimmunity Therapy

Updated Category News Views 217

Cabaletta Bio's Progress: A Focus on Innovative Therapies Cabaletta Bio, Inc. (Nasdaq: CABA) is making significant strides in the field of biotechnology, particularly in developing targeted cell therapies for autoimmune diseases. It's clear that the company is gearing up for a transformative journey with rese-cel, an investigational therapy designed to reset the immune...

Continue Reading
NBPE Share Buyback: A Strategic Move for Investors

Updated Category News Views 159

NB Private Equity Partners Announces Strategic Share Buyback In a significant turn of events, NB Private Equity Partners has declared its plans for a share buyback, a move that signals confidence in the company's future and aims to enhance shareholder value. This decision follows the recent approval from shareholders, making it an exciting development for investors...

Continue Reading
New Jersey Welcomes New York Plastic Surgical Group's Expansion

Updated Category News Views 253

New York Plastic Surgical Group Expands to New Jersey New York Plastic Surgical Group (NYPS Group), one of the leading plastic surgery practices in the nation, has announced an exciting expansion into New Jersey. The company has opened a new office in Englewood, providing residents with easy access to its comprehensive range of plastic, reconstructive, and aesthetic...

Continue Reading
Huasun Energy Expands Presence with Next2Sun Partnership in PV Tech

Updated Category News Views 416

Huasun Energy and Next2Sun Forge Exclusive Partnership Huasun Energy, recognized globally as the leading producer of heterojunction (HJT) solar products, has entered into an exclusive strategic partnership with Next2Sun, a notable player in vertical solar technology. This collaboration marks an important advancement for the integration of vertical photovoltaic (PV)...

Continue Reading